Immunotherapy strategies advance with Cabaletta Bio reporting CAR-T treatment efficacy in autoimmune conditions, planning pivotal trials. Albatroz pursues novel tumor metastasis prevention via extracellular matrix preservation. Monte Rosa received FDA IND clearance for an inflammatory disease molecular glue degrader targeting NLRP3 pathway. Deepcure nominated an oral STAT6 inhibitor mimicking dupilumab efficacy offering a convenient therapeutic option. These developments illustrate the expanding molecular tools combat diverse malignancies and immunological dysregulation.